html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

huperzine AFinding

Huperzine A increases Mini-Mental State Examination total score

raisesVery limited evidenceFinding

01 · The sentence it was drawn from

“Oral administration of HupA for 8-24 weeks (300-500 microg daily) led to significant improvements in MMSE and ADL.”

Quoted verbatim from Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

This finding among the 10 findings on its endpoint

huperzine A

Mini-Mental State Examination total score

raises

Who: Patients with Alzheimer's disease; meta-analysis of four randomized trials comparing huperzine A with placebo
Dose studied: 300-500 microg daily, oral, 8-24 weeks

Very limited evidencePMID 19221692 · 2009

02 · The study

Study: meta-analysis
Duration: not reported

Evidence, by strength

strong
moderate
limited
very limitedthis finding
insufficient

03 · The paper

Journal of neural transmission (Vienna, Austria

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

2009PMID 19221692doi 10.1007/s00702-009-0189-x

What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZFQ8J5J3A5693HKXDQDZSB